Clinical trials: Neovascular Age-related Macular Degeneration of All Subtypes
Neovascular Age-related Macular Degeneration of All Subtypes
Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START
Aflibercept (EYLEA®) induces a rapid reduction in central retinal thickness (CRT) for patients suffering from neovascular age-related-macular degeneration.1 This early dramatic reduction in CRT is already observed through week 4.
- Trial name
- START (NCT02246829)
- Testing
- Intravitreal injection
- Where
- 10 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bordeaux